- Home
- USAU vs ALDX Comparison
USAU vs ALDX Comparison
Compare USAU & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USAU | ALDX |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.1M | 293.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | USAU | ALDX |
|---|---|---|
| Price | $20.10 | $4.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $22.83 | $9.50 |
| AVG Volume (30 Days) | 403.2K | ★ 1.3M |
| Earning Date | 12-10-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $36.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.27 | $1.14 |
| 52 Week High | $23.44 | $7.20 |
Technical Indicators
Market Signals| Indicator | USAU | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 55.92 | 45.16 |
| Support Level | $19.30 | $3.95 |
| Resistance Level | $20.94 | $4.33 |
| Average True Range (ATR) | 1.18 | 0.27 |
| MACD | -0.11 | -0.04 |
| Stochastic Oscillator | 38.24 | 33.32 |
Price Performance
Historical ComparisonAbout USAU U.S. Gold Corp.
U.S. Gold Corp is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada, and the Challis Gold Project in Idaho.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.